Mickaël Le Douget
Novartis (China)(CN)
Publications by Year
Research Areas
Fibroblast Growth Factor Research, Epigenetics and DNA Methylation, Hippo pathway signaling and YAP/TAZ, Eosinophilic Disorders and Syndromes, Plant Surface Properties and Treatments
Most-Cited Works
- → Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase(2011)487 cited
- → FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor(2012)360 cited
- → The First Class of Small Molecules Potently Disrupting the YAP‐TEAD Interaction by Direct Competition(2022)43 cited
- → Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP‐TEAD Protein‐Protein Interaction Inhibitors(2023)22 cited
- → Abstract B246: NVP-BGJ398: A potent and selective inhibitor of the fibroblast growth factor receptor family.(2011)2 cited
- → Abstract 854: Patient stratification strategies for NVP-BGJ398, a selective pan-FGFR inhibitor in phase I clinical trials(2012)1 cited
- → Front Cover: The First Class of Small Molecules Potently Disrupting the YAP‐TEAD Interaction by Direct Competition (ChemMedChem 19/2022)(2022)1 cited
- → Data from FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor(2023)
- → Supplementary Table 5 from FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor(2023)